The company is one of the first to receive a “platform technology designation,” which could speed the review of certain gene ...

It’s the world’s largest research-focused patient organization for one of the most prevalent forms of muscular dystrophy. The FSHD Society is working toward a cure to end the pain ...

Phil Grant, 61, from Charlbury, Oxfordshire, has been volunteering for Muscular Dystrophy UK, the leading charity for more ...

The campaign to commemorate the work of the Muscular Dystrophy Association was created in partnership with agency Yes&.

The whir of circular saws and the thud of hammers broke the morning quiet in a North Seattle neighborhood on May 31, as seven ...

What if you'd invested in Catalyst Pharmaceutical (CPRX) ten years ago? It may not have been easy to hold on to CPRX for all that time, but if you did, how much would your investment be worth today?

Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with SM ...

Pfizer’s stock has dropped 25% from its recent high, raising questions about whether it's a buy at $23. Pipeline failures and ...

Schloegel Design Remodel partners with the Olivia Bloomfield Foundation to give away a custom bathroom to a family in need.

Satellos Bioscience Chief Scientific Officer discusses early-stage trials of the company's Duchenne muscular dystrophy drug, ...

Phil Lambert, Ph.D., chief scientific officer of Satellos Bioscience Inc., explains the mechanism of action of the company's experimental Duchenne muscular dystrophy drug, SAT-3247, and the thinking ...